

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

September 1, 2022

AGENDA ITEM

PRESIDER/PRESENTER(S)

Thursday, September 1, 2022

10:00	Welcome & Introductions	Dr. Grace Lee (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
10:15	Coronavirus Disease 2019 (COVID-19) Vaccines	
	Introduction	Dr. Matthew Daley (ACIP, WG Chair)
	Update on SARS-CoV-2 Variants and the Epidemiology of COVID-19	Dr. Heather Scobie (CDC/NCIRD)
	Immunology of SARS-CoV-2 variants	Dr. Natalie Thornburg (CDC/NCIRD)
	Updates to COVID-19 vaccine effectiveness in the United States	Dr. Ruth Link-Gelles (CDC/NCIRD)
	COVID-19 vaccine safety updates	Dr. Tom Shimabukuro (CDC/NCEZID)
12:00	Break	
12:15	Public Comment	
12:45	Break	
1:00	Moderna COVID-19 Bivalent vaccine (Original and Omicron BA.4/BA.5) Pfizer/BioNTech COVID-19 Omicron-modified Bivalent vaccine candidate	Dr. Jacqueline Miller (Moderna) Dr. Kena Swanson (Pfizer)
2:30	Break	
2:45	Evidence to recommendation Framework: Bivalent COVID-19 vaccine booster doses Clinical Considerations update	Dr. Sara Oliver (CDC/NCIRD) Dr. Elisha Hall (CDC/NCIRD)
4:30	VOTE Pfizer-BioNTech COVID-19 vaccine, Bivalent in individuals ages 12 years and older Moderna COVID-19 vaccine, Bivalent in individuals ages 18 years and older	Dr. Sara Oliver (CDC/NCIRD)
5:00	Adjourn	

Acronyms

CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
COVID-19	Coronavirus disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/DDID]
NCIRD	National Center for Immunization & Respiratory Diseases [of CDC/DDID]
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/DDID]
NIAID	National Institute of Allergy and Infectious Diseases
OIDP	Office of Infectious Disease and HIV/AIDS Policy
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
WG	Work Group
WHO	World Health Organization
VaST	COVID-19 Vaccine Safety Technical (VaST) Work Group
VE	Vaccine Effectiveness